SCHEMBL671749

SCHEMBL671749

CCC(C)(C#Cc1cc(NCc2cnn(C)c2)c(C(=O)OC)s1)CC

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PDE10A Q9Y233 5/20 0.34
RAF1 P04049 6/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HPGD P15428 1/20 0.34
ALDH1A1 P00352 2/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MAPK14 Q16539 1/20 0.34
ACACB O00763 1/20 0.34
TNF P01375 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
LMNA P02545 1/20 0.33
PDE1A P54750 1/20 0.33
PDE1B Q01064 1/20 0.33
PDE1C Q14123 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL669609 0.91 MEN1 (0.38) MEN1KMT2AHSD17B10PDE10ARAF1
SCHEMBL671748 0.77 RAF1 (0.31) RAF1
SCHEMBL668932 0.72 KDM4C (0.39) MEN1KMT2APDE10ARAF1L3MBTL1
SCHEMBL669903 0.72 RAF1 (0.44) PDE10ARAF1MAPK14
SCHEMBL670261 0.72 MCHR1 (0.35) RAF1
SCHEMBL668661 0.71 TRPM5 (0.38) RAF1SMN1; SMN2LMNA
SCHEMBL673730 0.69 RAF1 (0.41) PDE10ARAF1
SCHEMBL670263 0.68 RAF1 (0.33) RAF1ALDH1A1MAPK14
SCHEMBL15511618 0.67 NR1I2 (0.35) RAF1
SCHEMBL324986 0.67 CYP2E1 (0.37) RAF1ALDH1A1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2606041-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2013-06-26 EP disclosed
WO-2012024363-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-23 WO disclosed